Barely Significant
← all excerpts

Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial.

Rheumatol Immunol Res · 2026 · PMC13066660 · PMID 41969817

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

did not reach statistical significanceP > 0.05actually significant
The 300 mg group showed numerically greater improvement compared to placebo; however, the difference did not reach statistical significance ( P > 0.05).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.